Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma.
Cigliano A, Gigante I, Serra M, Vidili G, Simile MM, Steinmann S, Urigo F, Cossu E, Pes GM, Dore MP, Ribback S, Milia EP, Pizzuto E, Mancarella S, Che L, Pascale RM, Giannelli G, Evert M, Chen X, Calvisi DF. Cigliano A, et al. Among authors: evert m. J Exp Clin Cancer Res. 2024 Sep 6;43(1):253. doi: 10.1186/s13046-024-03177-7. J Exp Clin Cancer Res. 2024. PMID: 39243039 Free PMC article.
Aberrant fucosylation sustains the NOTCH and EGFR/NF-κB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
Ament CE, Steinmann S, Evert K, Pes GM, Ribback S, Gigante I, Pizzuto E, Banales JM, Rodrigues PM, Olaizola P, Wang H, Giannelli G, Chen X, Evert M, Calvisi DF. Ament CE, et al. Among authors: evert m, evert k. Hepatology. 2023 Dec 1;78(6):1742-1754. doi: 10.1097/HEP.0000000000000322. Epub 2023 Feb 16. Hepatology. 2023. PMID: 36789652
Correction: CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype.
Mancarella S, Serino G, Gigante I, Cigliano A, Ribback S, Sanese P, Grossi V, Simone C, Armentano R, Evert M, Calvisi DF, Giannelli G. Mancarella S, et al. Among authors: evert m. J Exp Clin Cancer Res. 2023 Apr 18;42(1):88. doi: 10.1186/s13046-023-02661-w. J Exp Clin Cancer Res. 2023. PMID: 37069577 Free PMC article. No abstract available.
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance.
Calvisi DF, Boulter L, Vaquero J, Saborowski A, Fabris L, Rodrigues PM, Coulouarn C, Castro RE, Segatto O, Raggi C, van der Laan LJW, Carpino G, Goeppert B, Roessler S, Kendall TJ, Evert M, Gonzalez-Sanchez E, Valle JW, Vogel A, Bridgewater J, Borad MJ, Gores GJ, Roberts LR, Marin JJG, Andersen JB, Alvaro D, Forner A, Banales JM, Cardinale V, Macias RIR, Vicent S, Chen X, Braconi C, Verstegen MMA, Fouassier L; CCA Model Consortium. Calvisi DF, et al. Among authors: evert m. Nat Rev Gastroenterol Hepatol. 2023 Jul;20(7):462-480. doi: 10.1038/s41575-022-00739-y. Epub 2023 Feb 8. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36755084 Free article. Review.
Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre.
Scheiter A, Hierl F, Lüke F, Keil F, Heudobler D, Einhell S, Klier-Richter M, Konstandin NP, Weber F, Scheiter A, Kandulski A, Schlosser S, Cosma LS, Tews H, Weiss ARR, Grube M, Bumes E, Hau P, Proescholdt M, Steger F, Troeger A, Haferkamp S, Reibenspies LE, Schnabel MJ, Schulz C, Drexler K, Hatzipanagiotou ME, Seitz S, Klinkhammer-Schalke M, Unberath P, Calvisi DF, Pukrop T, Dietmaier W, Evert M, Utpatel K. Scheiter A, et al. Among authors: evert m. Br J Cancer. 2023 Apr;128(6):1134-1147. doi: 10.1038/s41416-022-02120-x. Epub 2022 Dec 26. Br J Cancer. 2023. PMID: 36572733 Free PMC article.
261 results